News
Eutelsat Wins "strategic Transaction of the Year” Award for Its Investment in OneWeb
Regulatory News:
Eutelsat communications (Euronext Paris: ETL) is delighted to receive the "Strategic Transaction of the Year” award at this year's World Satellite Business Week in recognition of
![ExxonMobil and Scepter, Inc. to Deploy Satellite Technology for Real-Time Methane Emissions Detectionhttp://upload.wikimedia.org/wikipedia/commons/1/18/Exxon_Mobil_Logo.svg: By KUsam at en.wikipedia. Later version(s) were uploaded by Cheeselouise at en.wikipedia. [Public domain], from Wikimedia Commons](https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZWc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--c4dbe3169ae447c9c41bd56bfd50efcdfdd87d64/Exxon_Mobil_Logo.svg?locale=us){kind=logo}
ExxonMobil and Scepter, Inc. to Deploy Satellite Technology for Real-Time Methane Emissions Detection
ExxonMobil and Scepter, Inc. have agreed to work together to deploy advanced satellite technology and proprietary data processing platforms to detect methane emissions at a global scale. The
MedMen Now Offers Delivery Services Across Florida
MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a leading cannabis retailer with operations across the nation, today announced delivery services for medical cannabis
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results
Form 8.3 - The Vanguard Group, Inc.: NortonLife Lock Inc.
Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pfizer to Acquire Arena Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical
DGAP-News: GEA Group Aktiengesellschaft: A Capital Market Information
DGAP-News: Deutsche Wohnen SE: CFO Philip Grosse joins Vonovia
Nine in 10 Insurance Leaders in Europe Say Customer Experience is the Top Driver of Digital Transformation
Demand for improved customer experience is the top driver of digital transformation in Europe’s insurance industry, but with growing digitalization, insurers report increasing security
Northern Trust Launches New Climate Focus Reporting
Northern Trust (Nasdaq: NTRS) has further enhanced its suite of environmental, social and governance (ESG) investment analytics to deliver new climate risk reporting for global institutional
DGAP-News: Vonovia SE: Vonovia SE expands Management Board
Eurofins Technologies launches new Lateral Flow Reader RapidScan ST5-W as a single platform validated for multiple food and environmental rapid tests
Eurofins Technologies (Paris:ERF), a supplier of test kits and systems for laboratory analyses, announces the launch of its new RapidScan ST5-W lateral flow reader, specifically designed for field
Vifor Pharma comments on media speculation
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this
Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final
Gensource Potash Announces Filing of Base Shelf Prospectus
Gensource Potash Corporation (“Gensource” or the “Company”) (TSXV: GSP, AIM: GSP) today announced that it has filed and obtained a final receipt (the “Receipt”) for a final short form base shelf
Elliptic Labs Signs Software License Agreement with New Smartphone Customer for Seven Smartphone Models
Elliptic Labs (EuroNext Growth: ELABS.OL), a global AI software company and the world leader in AI Virtual Smart SensorsTM, has signed a license agreement with a new Asia-based smartphone
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting
Regulatory News:
MaaT Pharma (EURONEXT: MAAT - the “Company“), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving
DGAP-News: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL